Cargando…

The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis

BACKGROUND: This meta-analysis was conducted to evaluate the efficacy of the treat-repair-treat (TRT) strategy in the treatment of severe pulmonary arterial hypertension with congenital heart disease (PAH-CHD). METHODS: PubMed, EMBASE, Cochrane and Web of Science online databases were searched by tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhiyuan, Li, Xiaobing, Li, Mengxuan, Peng, Jun, Zhang, Huijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662905/
https://www.ncbi.nlm.nih.gov/pubmed/37986143
http://dx.doi.org/10.1186/s12872-023-03606-z
_version_ 1785148611083894784
author Wang, Zhiyuan
Li, Xiaobing
Li, Mengxuan
Peng, Jun
Zhang, Huijun
author_facet Wang, Zhiyuan
Li, Xiaobing
Li, Mengxuan
Peng, Jun
Zhang, Huijun
author_sort Wang, Zhiyuan
collection PubMed
description BACKGROUND: This meta-analysis was conducted to evaluate the efficacy of the treat-repair-treat (TRT) strategy in the treatment of severe pulmonary arterial hypertension with congenital heart disease (PAH-CHD). METHODS: PubMed, EMBASE, Cochrane and Web of Science online databases were searched by two independent investigators for studies that used the TRT strategy for PAH-CHD, and the retrieved studies were reviewed by a third investigator. The main outcomes were pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), 6-minute walk distance (6MWD), and transcutaneous oxygen saturation (SpO(2)). The changes were compared between follow-up and baseline. Stata version 14.0 was used for data analysis. A random-effects model was selected for meta-analysis. Subgroup analysis and meta-regression were used to find the source of heterogeneity. RESULTS: A total of 335 patients from 9 single-arm studies were included. Meta-analysis showed significant reductions in PAP and PVR and improvements in 6MWD and SpO(2) (PAP: SMD -2.73 95% CI -2.97, − 2.50 p = < 0.001; PVR: SMD -1.27 95% CI -1.53, − 1.02 p = < 0.001; 6MWD: SMD 1.88 95% CI 1.49, 2.27 p = < 0.001; SpO(2): SMD 3.72 95% CI 3.13, 4.32 p = < 0.001). Subgroup analysis showed that younger patients had better efficacy, and the change in SpO(2) was an indication for patient selection. The combined mortality rate was 5% at follow-up. CONCLUSIONS: In this meta-analysis, we demonstrated that the TRT strategy may have positive effects on haemodynamics and cardiac function in patients with severe PAH-CHD at short-term follow-up. Our analysis suggests that changes in age and SpO(2) may be related to patient prognosis. TRIAL REGISTRATION: The protocol was registered on the PROSPERO website with the registration number CRD42022366552. The relevant registration information can be obtained from the website https://www.crd.york.ac.uk/prospero/#searchadvanced.
format Online
Article
Text
id pubmed-10662905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106629052023-11-20 The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis Wang, Zhiyuan Li, Xiaobing Li, Mengxuan Peng, Jun Zhang, Huijun BMC Cardiovasc Disord Research BACKGROUND: This meta-analysis was conducted to evaluate the efficacy of the treat-repair-treat (TRT) strategy in the treatment of severe pulmonary arterial hypertension with congenital heart disease (PAH-CHD). METHODS: PubMed, EMBASE, Cochrane and Web of Science online databases were searched by two independent investigators for studies that used the TRT strategy for PAH-CHD, and the retrieved studies were reviewed by a third investigator. The main outcomes were pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), 6-minute walk distance (6MWD), and transcutaneous oxygen saturation (SpO(2)). The changes were compared between follow-up and baseline. Stata version 14.0 was used for data analysis. A random-effects model was selected for meta-analysis. Subgroup analysis and meta-regression were used to find the source of heterogeneity. RESULTS: A total of 335 patients from 9 single-arm studies were included. Meta-analysis showed significant reductions in PAP and PVR and improvements in 6MWD and SpO(2) (PAP: SMD -2.73 95% CI -2.97, − 2.50 p = < 0.001; PVR: SMD -1.27 95% CI -1.53, − 1.02 p = < 0.001; 6MWD: SMD 1.88 95% CI 1.49, 2.27 p = < 0.001; SpO(2): SMD 3.72 95% CI 3.13, 4.32 p = < 0.001). Subgroup analysis showed that younger patients had better efficacy, and the change in SpO(2) was an indication for patient selection. The combined mortality rate was 5% at follow-up. CONCLUSIONS: In this meta-analysis, we demonstrated that the TRT strategy may have positive effects on haemodynamics and cardiac function in patients with severe PAH-CHD at short-term follow-up. Our analysis suggests that changes in age and SpO(2) may be related to patient prognosis. TRIAL REGISTRATION: The protocol was registered on the PROSPERO website with the registration number CRD42022366552. The relevant registration information can be obtained from the website https://www.crd.york.ac.uk/prospero/#searchadvanced. BioMed Central 2023-11-20 /pmc/articles/PMC10662905/ /pubmed/37986143 http://dx.doi.org/10.1186/s12872-023-03606-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Zhiyuan
Li, Xiaobing
Li, Mengxuan
Peng, Jun
Zhang, Huijun
The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis
title The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis
title_full The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis
title_fullStr The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis
title_full_unstemmed The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis
title_short The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis
title_sort efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662905/
https://www.ncbi.nlm.nih.gov/pubmed/37986143
http://dx.doi.org/10.1186/s12872-023-03606-z
work_keys_str_mv AT wangzhiyuan theefficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT lixiaobing theefficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT limengxuan theefficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT pengjun theefficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT zhanghuijun theefficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT wangzhiyuan efficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT lixiaobing efficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT limengxuan efficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT pengjun efficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis
AT zhanghuijun efficacyofthetreatrepairtreatstrategyforseverepulmonaryarterialhypertensionassociatedwithcongenitalheartdiseaseametaanalysis